替吉奥胶囊联合奥沙利铂治疗晚期大肠癌的疗效分析

摘要

Objective: To evaluate the efficacy and toxicity of SI capsule combined with oxaliplatin in the treatment of advanced colorectal carcinoma. Methods:Using non - blinded randomized controlled trial,study group 18 cases, were treated by gonow (S - 1) capsule plus oxaliplatin Platinum,gonow (S — 1) capsule every day 80 mg/m , min 2 times. In controlled group 18 cases were treated,by oxaliplatin Platinum 85mg/m ,vein drops,3h,d1 ,Asia folic acid calcium 200mg/ m vein drops,2h,d1-5,Fluoride urine pyrimidine 300mg/ m vein drops,2h,d1-5. Results;In study group( CR + PR) RR was 56. 1% ,median survival time ( MST) 18. 6 months. In control group ( CR + PR) RR 44.4% .median survival time(MST) 16. 2 months. Major adverse reactions were haematological toxicity and gastrointestinal reactions. Conclusion: SI capsule combined with oxaliplatin is effective and tolerable in the treatment of patients with advanced colorectal carcinoma.%目的:观察替吉奥(S-1)胶囊联合奥沙利铂治疗晚期大肠癌的临床疗效和安全性.方法:采用非盲法随机对照试验.试验组18例,替吉奥(S-1)胶囊联合奥沙利铂,替吉奥(S-1)胶囊每天80 mg/m2,分2次,餐后口服,d1-14,奥沙利铂85mg/m2,静脉滴注,3h,d1,28天一周期；对照组18例,奥沙利铂85mg/m2,静脉滴注,3h,d1,亚叶酸钙200mg/m2静脉滴注,2h,d1-5,氟尿嘧啶300mg/m2静脉滴注,2h,d1-5,28天一周期.结果:试验组(CR+ PR) RR 56.1％,中位生存期(MST) 18.6个月,对照组(CR +PR)RR44.4％,中位生存期(MST) 16.2个月.主要不良反应为血液学毒性和胃肠道反应,试验组白细胞下降发生率66.7％对照组77.8％,试验组恶心、呕吐发生率44.4％,对照组66.7％.结论:替吉奥(S-1)胶囊胶囊联合奥沙利铂是治疗晚期大肠癌是一种安全有效的化疗方案.